{"id":10523,"date":"2010-06-01T16:35:01","date_gmt":"2010-06-01T16:35:01","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10523"},"modified":"2010-06-01T16:35:01","modified_gmt":"2010-06-01T16:35:01","slug":"maraviroc-150mg-once-daily-achieves-target-concentrations-with-atazanavirritonavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10523","title":{"rendered":"Maraviroc 150mg once-daily achieves target concentrations with atazanavir\/ritonavir"},"content":{"rendered":"<p><strong>www.hiv-druginteractions.org<\/strong><\/p>\n<p>The pharmacokinetics of maraviroc (150 mg once daily) and atazanavir\/ritonavir (300\/100 mg once-daily) were assessed in a pharmacokinetic sub-study of 15 HIV-positive volunteers.\u00a0 All subjects achieved, or exceeded, the targeted maraviroc Caverage of 75 ng\/ml. Steady state values for maraviroc AUC, Cmax and Cmin were 4330 ng.h\/ml, 650 ng\/ml and 37 ng\/ml, respectively. Efficacy and safety of this combination are currently being evaluated.<\/p>\n<p>Ref: Vourvahis M et al. Pharmacokinetics of QD maraviroc co-administered as part of a novel NRTI-sparing regimen with atazanavir\/ritonavir in HIV treatment-naive patients. 11th PK Workshop, 2010. Abstract 37. <\/p>\n<div><strong> <\/strong><\/div>\n","protected":false},"excerpt":{"rendered":"<p>www.hiv-druginteractions.org The pharmacokinetics of maraviroc (150 mg once daily) and atazanavir\/ritonavir (300\/100 mg once-daily) were assessed in a pharmacokinetic sub-study of 15 HIV-positive volunteers.\u00a0 All subjects achieved, or exceeded, the targeted maraviroc Caverage of 75 ng\/ml. Steady state values for &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,34],"tags":[134],"class_list":["post-10523","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-pk-and-drug-interactions","tag-pk-workshop-11th-2010"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10523"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10523\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}